NEW YORK (GenomeWeb News) – German protein research firm Protagen this week said it and MicroDiscovery are collaborating to identify and validate biomarkers.
Protagen will use its UNIArray technology platform while MicroDiscovery will incorporate its software for the analysis of complex biomarker panels as part of the collaboration.
Terms of the deal were not disclosed.
Based in Dortmund, Protagen last month announced it had raised €10 million ($14 million) in a second financing round. In a statement this week, Peter Schulz-Knappe, CSO and executive vice president of diagnostics for Protagen said the deal with Berlin-based MicroDiscovery "strengthens our position in biomarker development and supports the efficient development of marketable products."